Вы находитесь на странице: 1из 4

Research cooperation project

Curriculum Vitae

Name, surname Valdis Pirags

Date of birth 20.02.1961.
Address Elizabetes iela 69-13, Rīga LV1050
+ 371 29237760, (secretary) +371 67069307; pirags@latnet.lv
Nationality Latvian


1993. – 1995. University of Ruhr, Bochum, Germany Dr. med. magna cum laude

Medical Academy of Latvia;

1984. – 1990. Physician (ārsta grāds)
University of Rostock , Germany

1979. – 1984. University of Latvia, Faculty of Physics and



2012. - present Vice-dean

University of Latvia, Faculty of Medicine
Professor and Chair of
2005. – present
University of Latvia, Faculty of Medicine Internal Medicine

2001. – 2005. University of Latvia, Faculty of Medicine

Associate Professor

2000. – present Pauls Stradins Clinical University Hospital Head of the Clinic of
Internal Medicine


Latvian 5 5 5
English 5 5 5
German 5 5 5
Russian 5 5 5

PUBLICATIONS (more than 200 published papers and abstracts)
As the first author (2012-2013):

1. Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good
efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012 Sep;14(9):852-
2. Pīrāgs V, El Damassy H, Dąbrowski M, Gönen MS, Račická E, Martinka E, Giaconia J,
Stefanski A; B001 Study Investigators. Low risk of severe hypoglycaemia in patients with type 2
diabetes mellitus starting insulin therapy with premixed insulin analogues BID in outpatient
settings. Int J Clin Pract. 2012 Nov;66(11):1033-41.

As the co-author (2012-2013):

1. Fouqueray P, Pirags V, Inzucchi SE, Bailey CJ, Schernthaner G, Diamant M, Lebovitz HE. The
efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately
controlled with metformin monotherapy. Diabetes Care. 2013 Mar;36(3):565-8.
2. Rosen JB, Jimenez JG, Pirags V, Vides H, Hanson ME, Massaad R, McPeters G, Brudi P,
Triscari J. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared
with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic
cardiovascular disease. Diab Vasc Dis Res. 2013 May;10(3):277-86.
3. Jimenez JG, Rosen JB, Pirags V, Massaad R, Hanson ME, Brudi P, Triscari J.The efficacy and
safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment
strategies in diabetic subjects with and without metabolic syndrome. Diabetes Obes Metab. 2013
4. Skapare E, Konrade I, Liepinsh E, Strele I, Makrecka M, Bierhaus A, Lejnieks A, Pirags V,
Dambrova M. Association of reduced glyoxalase 1 activity and painful peripheral diabetic
neuropathy in type 1 and 2 diabetes mellitus patients. J Diabetes Complications. 2013 May-
5. Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, Sauer SK, Eberhardt M,
Schnölzer M, Lasitschka F, Neuhuber WL, Kichko TI, Konrade I, Elvert R, Mier W, Pirags V,
Lukic IK, Morcos M, Dehmer T, Rabbani N, Thornalley PJ, Edelstein D, Nau C, Forbes J,
Humpert PM, Schwaninger M, Ziegler D, Stern DM, Cooper ME, Haberkorn U, Brownlee M,
Reeh PW, Nawroth PP. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron
firing and causes hyperalgesia in diabetic neuropathy. Nature Med. 2012 Jun;18(6):926-33.
6. Kalnina I, Zaharenko L, Vaivade I, Rovite V, Nikitina-Zake L, Peculis R, Fridmanis D, Geldnere
K, Jacobsson JA, Almen MS, Pirags V, Schiöth HB, Klovins J. Polymorphisms in FTO and near
TMEM18 associate with type 2 diabetes and predispose to younger age at diagnosis of diabetes.
Gene. 2013 Jul 13.
7. Peculis R, Konrade I, Skapare E, Fridmanis D, Nikitina-Zake L, Lejnieks A, Pirags V, Dambrova
M, Klovins J. Identification of glyoxalase 1 polymorphisms associated with enzyme activity.
Gene. 2013 Feb 15;515(1):140-3.
8. Kalnina I, Geldnere K, Tarasova L, Nikitina-Zake L, Peculis R, Fridmanis D, Pirags V, Klovins J.
Stronger association of common variants in TCF7L2 gene with nonobese type 2 diabetes in the
Latvian population.Exp Clin Endocrinol Diabetes. 2012 Sep;120(8):466-8.

9. Ignatovica V, Latkovskis G, Peculis R, Megnis K, Schioth HB, Vaivade I, Fridmanis D, Pirags V,
Erglis A, Klovins J.Single nucleotide polymorphisms of the purinergic 1 receptor are not
associated with myocardial infarction in a Latvian population. Mol Biol Rep. 2012
10. Tarasova L, Kalnina I, Geldnere K, Bumbure A, Ritenberga R, Nikitina-Zake L, Fridmanis D,
Vaivade I, Pirags V, Klovins J. Association of genetic variation in the organic cation transporters
OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the
gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
Pharmacogenet Genomics. 2012 Sep;22(9):659-66.


 Head of the National Programme in Biomedicine and Public Health (Valsts pētījumu
programma, 2010-2013)
 Head of the National Programme in the Medical Science (Valsts pētījumu programma, 2006-
2009) "Multi-Disciplinary Research Consortium on Major Pathologies Threatening the Life
Expectancy and Quality of Life of the Latvian Population"
 Creation of the Unified Latvian Genome Database (2003-2009)
 Head of the Latvian Council of Science Project "Molecular and Genetic Characteristics of the
Nodular and Autoimmune Thyroid Diseases in Latvia (2004 -2007)
 Head of the Latvian Council of Science Project "Alleles of the HLA DR, DQ and other genes
predisposing to and protecting against the autoimmune thyrotoxicosis (2001-2003)
 Head of the Latvian Council of Science Project "Relationship of the protein kinase C beta gene
PRKCB1 to diabetes mellitus" (2000-2001)
 Head of the Latvian Council of Science Project "Predisposing and Protective Gene Alleles in
Patients with Graves'Disease" (1999-2001)

Participation in 5th and 6th Framework Programs funded by the European Commission:

 Head of the Latvian part of the EU FP6 Project "ScanBalt COMPETENCE REGION: a model
case to enchance European competitiveness in life sciences, genomics and biotechnology for
health on a global scale" (2004-2006)
 Co-chairman of the Latvian part of the EU FP5 Project "COGENE: Coordination of Genomes
Research Across Europe" (2002-2003)
Since 1997 conducted more than 50 randomized clinical trials (RCT) in patients with diabetes and
cardiovascular complications. Member of the international steering committees and operational
committees in many large-scale studies including TECOS, EXCEL, REWIND, DREAM, ORIGIN,
PROactive and others.

Endocrinology, Metabolic Diseases and Diabetes, Genome Databases, Genetics of Diabetes, Pathogenesis
of Diabetes and Diabetic Complications, Medical Education, Intracellular Signal Transduction.


1. Pauls Stradins Award of the Latvian Academy of Sciences for 2012

2. Distiguished Research Award for 2003 in the science category from the Kuwait Foundation

3. Karl-Oberdisse-Prize of the NRW Diabetes Society, Germany for 1996


since 2013 Current member of the Latvian Council of Science
Member, Editorial Board for medical journal Experimental and Clinical
since 2006
Endocrinology & Diabetes (Germany)
since 2004 President of the Baltic Atherosclerosis Society, board member since 2007
2005 – 2009 Council Member of the European Association for the Study of Diabetes
2005 – 2009 Executive Committee Member of the European Society of Endocrinology
1998 – 2007 President of the Latvian Association of Endocrinology, board member since 2011
Member of the Diabetes Education Study (DESG) at the European Association for
the Study of Diabetes
Review Editor for medical journals International Diabetes Monitor, Medical
Teacher, etc.
Member of the Working Group on Research on Stored Human Biological
Materials at the Council of Europe
2002. Member of the ScanBalt (Nordic-Baltic Biotech Network) Steering Group


__________________________/Valdis Pirags